Floatz logo

Cot

Cognitive Disorder

Evon Medics LLCUNKNOWNPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

131 Active assets in the Cognitive Disorder cohort.

Asset / SponsorPhaseRating
Nicotine
University of Southern California
Phase 2BBB
Oxybutynin
University of Alberta
Phase 4BBB
Quetiapine
Emory University
Phase 4BB
Rivastigmine
VA Office of Research and Development
Phase 4BB
Levodopa
Vanderbilt University Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Cot is also rated in:

amnestic disorderActive
CCC
Indicative · Phase 2
53 / 100
View asset →
Alzheimer diseaseActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →